Primary Care Diagnostic Accuracy Rivals Specialized Clinics
Blood-based biomarker tests are closing the diagnostic gap in Alzheimer’s care, matching the performance levels of specialized memory clinics. Data presented at the 2026 Alzheimer’s Association International Conference (AAIC) revealed that these tests prompted primary care physicians (PCPs) to alter clinical management plans in more than half of all cases evaluated.
Closing the Diagnostic Gap
Confirming an Alzheimer’s diagnosis has historically been limited to specialists using PET scans and spinal fluid analysis. A study led by Sebastian Palmqvist, MD, PhD, a neurologist at Lund University in Sweden, set out to determine if blood tests could simplify this process.
Performance Data Across 1,310 Patients
The research followed 1,310 patients struggling with mild cognitive impairment or dementia. The cohort was split between 927 patients seen by dementia specialists and 383 evaluated by PCPs. Every physician used the PrecivityAD2 blood test—which measures phosphorylated tau and amyloid beta levels—to guide their diagnosis.
The results were stark. Among specialists, diagnostic accuracy jumped from 73% to 93% after viewing the test results. PCPs saw an even greater improvement, with accuracy rising from 62% to 88%.
The 2026 AAIC findings highlight a shift in real-world decision-making: PCPs changed their initial patient management plans in 62.8% of cases after receiving blood test data. Rather than triggering a flood of new referrals, the tests allowed for more precise care.
When a blood test returned a negative result, PCPs were able to confidently rule out Alzheimer’s disease, curbing unnecessary specialist referrals. The negative predictive value (NPV) for PCPs hit 87%, nearly matching the 89% NPV recorded by dementia specialists.
The Future of Routine Screening
These biomarkers act as a powerful supplement to, not a replacement for, standard clinical judgment. Sheena Aurora, MD, Vice President of Medical Affairs at the Alzheimer’s Association, noted that while the high diagnostic performance was expected, the magnitude of the impact on day-to-day clinical practice was significant.
By providing objective data, these tests help providers decide whether a patient needs specialist evaluation or if an alternative cause for cognitive impairment is at play. The mounting evidence supports integrating these tests into routine primary care to reduce diagnostic delays and streamline the path to appropriate patient management.